How Analysts Rated Bayer AG (ETR:BAYN) Last Week?

Share with your friends


Out of 19 analysts covering Bayer (ETR:BAYN), 10 rate it “Buy”, 0 “Sell”, while 9 “Hold”. This means 53% are positive. Bayer was the topic in 56 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Below is a list of Bayer AG (ETR:BAYN) latest ratings and price target changes.

11/12/2015 Broker: Independent Research Rating: Buy New Target: €148.00 Upgrade
11/12/2015 Broker: HSBC Rating: Buy New Target: €138.00 Upgrade
10/12/2015 Broker: Equinet Rating: Neutral New Target: €134.00 Maintain
10/12/2015 Broker: BNP Paribas Rating: Neutral New Target: €129.00 Maintain
08/12/2015 Broker: Jefferies Rating: Hold New Target: €125.00 Maintain
03/12/2015 Broker: Bankhaus Lampe Rating: Buy New Target: €149.00 Upgrade
01/12/2015 Broker: Deutsche Bank Rating: Buy New Target: €155.00 Upgrade
20/11/2015 Broker: DZ-Bank AG Rating: Buy Upgrade
17/11/2015 Broker: Credit Suisse Rating: Outperform New Target: €135.00 Upgrade
13/11/2015 Broker: Bernstein Rating: Outperform New Target: €152.00 Upgrade

The stock decreased 2.27% or EUR 2.6 on December 11, hitting EUR 112.1. About 2.72M shares traded hands or 47.03% up from the average. Bayer AG (ETR:BAYN) has 0.00% since May 15, 2015 and is . It has outperformed by 4.42% the S&P500.

Another recent and important Bayer AG (ETR:BAYN) news was published by which published an article titled: “3 Reasons Value Stock Investors Will Love Bayer AG (BAYRY)” on July 08, 2015.

Bayer AG is a strategic management holding company. The company has a market cap of 91.81 billion EUR. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 25.45 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.

Bayer AG - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Add Comment